Scholars Central

Conference abstractPublished 29 May 2017

Drug Delivery Across the Blood Brain Barrier

Authors: Alain L. Fymat

International Institute of Medicine and Science California, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are approximately 400 known neural disorders some of which being due to a disruption or failure of the blood brain barrier (BBB) such as, for example: meningitis (an inflammation of the meninges or membranes surrounding the brain and spinal cord); epilepsy (chronic or acute seizures caused by inflammation); multiple sclerosis (MS - a disease of the immune system or/and the breaking down of the BBB in a section of the brain or spinal cord); Alzheimer disease (AD - a disease in which amyloid beta contained in blood plasma enter the brain and adhere to the surface of astrocytes); possibly prion and prion-like diseases such as Parkinson disease (PD) and AD; HIV encephalitis (a precursor of HIV-associated dementia in which latent HIV can cross the BBB inside circulating monocytes in the blood stream); and systemic inflammation (sterile or infectious) that may lead to effects on the brain, cause sickness behavior and induce or/and accelerate brain diseases such as MS and PD. There are currently active investigations into treatments for a compromised BBB. As a consequence of the growing aging population, many such neurodegenerative diseases, cancer and infections of the brain will become more prevalent. Of interest here are those disorders requiring treatment by delivery of drugs across the brain protective barriers. I will review the difficulties inherent in the delivery of drugs across the BBB in the treatment oif the above neurological disorders, and discuss the mechanisms for drug targeting both “through” and “behind” the BBB. I will also suggest approaches for the enhancement of drug delivery including physiological approaches, chemical and biological delivery, disruption of the BBB system, the use of molecular Trojan horse systems, and the various nanoparticle and nano delivering devices.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • SubjectHaematology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Alain L. Fymat”